The many facets of immune-mediated thrombocytopenia: …
2024年1月1日 · Immune thrombocytopenia (ITP) is a rare autoimmune condition, due to peripheral platelet destruction through antibody-dependent cellular phagocytosis, complement …
Clinical Trial for Primary Immune Thrombocytopenia. | Pfizer
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This …
特发性血小板减少性紫癜 - 维基百科，自由的百科全书
特发性血小板减少性紫癜 （英語： Idiopathic thrombocytopenic purpura，ITP）是因 血小板 免疫性破坏，导致 外周血 中血小板减少的出血性 疾病。 是最常见的 血小板减少性紫癜，它是一 …
Long-term management of chronic immune thrombocytopenic purpura …
According to the recent international consensus report, 1 primary immune thrombocytopenia (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia, defined …
原发免疫性血小板减少症 - 百度百科
原发免疫性血小板减少症（ITP），以往称特发性血小板减少性 紫癜，是一种获得性自身免疫性疾病。 是临床所见血小板计数减少引起最常见出血性疾病。 通过对患者血小板相关抗体的研 …
Immune Thrombocytopenia (ITP) Clinical Trials - Mayo Clinic …
This study is designed to clarify the effects of the CXCR5 inhibitor, PF-06835375 on platelet counts in participants with moderate-to-severe primary Immune Thrombocytopenia (ITP). The …
PF-06835375 in Primary Immune Thrombocytopenia - ICH GCP
2021年9月27日 · This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune …
PF-06835375 在 原发性免疫性血小板减少症-临床试验注册中心 …
2021年9月27日 · 这是 PF-06835375 在患有原发性免疫性血小板减少症 (ITP) 的成年参与者中进行的一项 2 期、开放标签、单组、多中心、多次皮下注射、安全性和有效性研究。 本研究将关 …
Safety and Efficacy Study of PF-06835375 in Primary Immune ...
This study is designed to clarify the effects of the CXCR5 inhibitor, PF-06835375 on platelet counts in participants with moderate-to-severe primary Immune Thrombocytopenia (ITP). …
Safety and Efficacy Study of PF-06835375 in Primary ITP - PDSA
Pfizer is conducting a phase 2 multicenter study to look at the safety and efficacy of using a drug called PF-06835375 for treatment of adults (between 18-70 years) with persistent or chronic …